Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
70.9M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
39.3M
-
Shares change
-
-511K
-
Total reported value, excl. options
-
$345M
-
Value change
-
-$2.39M
-
Number of buys
-
59
-
Number of sells
-
-45
-
Price
-
$8.77
Significant Holders of C4 Therapeutics, Inc. - Common Stock (CCCC) as of Q3 2022
132 filings reported holding CCCC - C4 Therapeutics, Inc. - Common Stock as of Q3 2022.
C4 Therapeutics, Inc. - Common Stock (CCCC) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.3M shares
of 70.9M outstanding shares and own 55.42% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS INC (5.93M shares), ArrowMark Colorado Holdings LLC (5.09M shares), BlackRock Inc. (3.46M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.96M shares), RTW INVESTMENTS, LP (2.82M shares), VANGUARD GROUP INC (2.02M shares), STATE STREET CORP (1.96M shares), Bain Capital Life Sciences Investors, LLC (1.64M shares), Soleus Capital Management, L.P. (1.44M shares), and PICTET ASSET MANAGEMENT SA (1.31M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.